Roche in $600m deal for Parkinson's antibody program
This article was originally published in Scrip
Executive Summary
Roche is paying Elan spin-out Prothena $45m in the near term as part of a new collaboration to develop and commercialize antibodies that target alpha-synuclein. The agreement includes PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease, which is currently in preclinical development and is expected to enter Phase I trials in 2014.
You may also be interested in...
Prothena Gives Amyloidosis Drug Birtamimab A Second Chance
With post hoc analysis from a 2018 study showing a survival benefit in patients at high risk for early mortality, Prothena negotiated a path forward with the US FDA for approval in AL amyloidosis.
After Phase III Amyloidosis Failure Prothena Slashes Workforce In Restructuring
In the backlash following the failure of its late-stage amyloidosis drug, Prothena has announced it will cut 57% of its workforce as part of a restructuring plan.
Prothena CEO Dale Schenck Dies From Pancreatic Cancer
Prothena CEO Dale Schenk, the scientist behind innovative medicines that included bapineuzumab and Tysabri, died from pancreatic cancer on Sept. 30 – less than two years after he revealed his diagnosis.